Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,605 people, and is a component of the S&P 500.

Earnings season is a go, with the country's biggest banks reporting this week. There is also some fresh inflation data pending. Last week, the first full week of trading in 2026, saw the Dow Jones Industrial Average pop 2.3%, the S&P 500 rise 1.6%, and the Nasdaq gain 1.9%. On the earnings calendar, JPMorgan Chase and The Bank of New York Mellon report on Tuesday, along with Delta Air Lines; Bank of America, Wells Fargo, and Citigroup report on Wednesday; Morgan Stanley, Goldman Sachs, and BlackRock report on Thursday; and Charles Schwab, PNC Financial, and State Street report on Friday. This earnings season follows a strong previous quarter. In 3Q, profits for S&P 500 companies were up a hefty 15% compared to the prior-year quarter. That followed 13% growth in 2Q EPS and 14% growth in 1Q EPS, according to LSEG I/B/E/S. In 3Q, Information Technology was the leading sector, up 31%, and Energy was at the bottom, down 2%. On the economic calendar this week, the big day is Tuesday, when the Consumer Price Index (CPI) inflation indicator is reported for December. The consensus call is for headline CPI to stay steady at 2.7% and for core CPI to inch up to 2.7%, from 2.6% the previous month. Retail sales and the Producer Price Index (PPI) are both due out on Wednesday. And finally, roughly 10 Federal Reserve officials will speak publicly. Turning to other data, the Atlanta Fed GDPNow measure jumped to a forecast of 5.1% growth in the fourth quarter. That's up from last week's forecast of 3.0%. The Cleveland Fed Inflation Nowcast predicts a 2.6% rate for December and 2.2% in January. Mortgage rates ticked up one basis points last week, with the average 30-year fixed-rate mortgage now at 6.16%, according to FreddieMac. Gas prices went down a penny and are now at an average of $2.80 per gallon for regular gas. Looking ahead, the next Federal Open Market Committee meeting is on January 28. Odds for a rate cut at the meeting fell to 5% from 15% following the jobs report last week, this according to the CME FedWatch rate tool. Assuming there is no cut, the odds are at 28% for a cut at the meeting on March 18. Taking a deeper dive into performance for the short year-to-date, a leading industrialized global stock market index, the ETF EFA, is up 2% year to date, while the leading emerging market ETF EEM is up 4%. U.S. growth stocks are flat year to date looking at ETF IWF, while value stocks (ETF IWD) are higher by 3%. In other asset classes for the year to date, AGG bonds are flat, gold is up 3%, crude oil is up 1%, and Bitcoin is up 3%. The U.S. dollar is up 1%, tracking DXY. The VIX Volatility Index settled Friday at 14.49, down from a high of 26 in late November. Here is a look at sectors so far in 2026. Energy (+2.1%) and Industrials (+1.9%) are the top performers in these early days, with Materials (+1.5%) and Utilities (+1.2%) close behind. Meanwhile, Information Technology and Real Estate are flat, while the Financials sector is up 0.2% and Healthcare is up 0.4%. Defensive sectors stack up as follows: Communication Services (-0.4%), Consumer Staples (-0.2%), and Consumer Discretionary (-1.1%).

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).